Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionglucuronosyltransferase activity

UGT2A2 UGT2A1 UGT2B15 UGT2B17

2.75e-05351004GO:0015020
GeneOntologyMolecularFunctiondiacylglycerol-dependent, calcium-independent serine/threonine kinase activity

PRKCE PRKCH

7.42e-0531002GO:0004699
GeneOntologyMolecularFunctionapolipoprotein binding

LPL LRP1 LRP6

1.31e-04201003GO:0034185
GeneOntologyMolecularFunctiontransporter activity

LRRC8E TRPC1 TTYH3 SLC1A5 RYR2 ABCB1 SLC6A6 MFSD14A SLC44A1 SLC16A4 SCN7A SLC28A1 TMEM184C LRP6 LRP5 SLC26A11 SLC27A2

2.13e-04128910017GO:0005215
GeneOntologyMolecularFunctiontransmembrane transporter activity

LRRC8E TRPC1 TTYH3 SLC1A5 RYR2 ABCB1 SLC6A6 MFSD14A SLC44A1 SLC16A4 SCN7A SLC28A1 LRP6 LRP5 SLC26A11 SLC27A2

2.45e-04118010016GO:0022857
GeneOntologyBiologicalProcesscellular glucuronidation

UGT2A2 UGT2A1 UGT2B15 UGT2B17 PRKCE

4.40e-0821995GO:0052695
GeneOntologyBiologicalProcessglucuronate metabolic process

UGT2A2 UGT2A1 UGT2B15 UGT2B17 PRKCE

1.40e-0726995GO:0019585
GeneOntologyBiologicalProcessuronic acid metabolic process

UGT2A2 UGT2A1 UGT2B15 UGT2B17 PRKCE

1.40e-0726995GO:0006063
GeneOntologyBiologicalProcesscirculatory system process

DOCK4 DRD2 TRPC1 F5 SLC1A5 RYR2 ABCB1 SLC6A6 SLC44A1 SCN7A WDR35 LRP1 LRP5 GSTO1

1.05e-057339914GO:0003013
GeneOntologyBiologicalProcesscellular catabolic process

TRHDE TMEM150B DRD2 ACER1 TRIM58 ETFDH ADAMTS13 ALDH1L1 WDFY4 GUSB LPL LRP1 UGT2B15 UGT2B17 ACMSD GSTO1 ARHGAP11B SLC27A2

2.57e-0512539918GO:0044248
GeneOntologyBiologicalProcesstransport across blood-brain barrier

SLC1A5 ABCB1 SLC6A6 SLC44A1 LRP1

6.23e-0587995GO:0150104
GeneOntologyBiologicalProcessvascular transport

SLC1A5 ABCB1 SLC6A6 SLC44A1 LRP1

6.58e-0588995GO:0010232
GeneOntologyBiologicalProcesspositive regulation of sequestering of calcium ion

RYR2 PRKCE GSTO1

9.83e-0519993GO:0051284
GeneOntologyBiologicalProcessestablishment of blood-brain barrier

ABCB1 LRP6 LRP5

9.83e-0519993GO:0060856
GeneOntologyBiologicalProcesscarboxylic acid transport

LRRC8E DRD2 TTYH3 SLC1A5 ABCB1 SLC6A6 SLC16A4 SLC26A11 SLC27A2

1.59e-04410999GO:0046942
GeneOntologyBiologicalProcessorganic acid transport

LRRC8E DRD2 TTYH3 SLC1A5 ABCB1 SLC6A6 SLC16A4 SLC26A11 SLC27A2

1.65e-04412999GO:0015849
GeneOntologyBiologicalProcessNorrin signaling pathway

LRP6 LRP5

2.26e-045992GO:0110135
GeneOntologyBiologicalProcessnegative regulation of cytosolic calcium ion concentration

DRD2 RYR2 LRP1

2.28e-0425993GO:0051481
DomainLRP5/6

LRP6 LRP5

2.61e-052962IPR017049
DomainUPF0220

TMEM50A TMEM50B

2.61e-052962PF05255
DomainUPF0220

TMEM50A TMEM50B

2.61e-052962IPR007919
DomainLdl_recept_b

LRP1 LRP6 LRP5

4.60e-0514963PF00058
DomainLDLRB

LRP1 LRP6 LRP5

4.60e-0514963PS51120
Domain-

TENM4 LRP1 LRP6 LRP5

4.70e-05399642.120.10.30
DomainLY

LRP1 LRP6 LRP5

5.73e-0515963SM00135
DomainLDLR_classB_rpt

LRP1 LRP6 LRP5

5.73e-0515963IPR000033
Domain-

LRP1 LRP6 LRP5 ALK

9.06e-05469644.10.400.10
Domain6-blade_b-propeller_TolB-like

TENM4 LRP1 LRP6 LRP5

9.06e-0546964IPR011042
DomainLDLRA_1

LRP1 LRP6 LRP5 ALK

1.07e-0448964PS01209
DomainLDLRA_2

LRP1 LRP6 LRP5 ALK

1.16e-0449964PS50068
DomainLDrepeatLR_classA_rpt

LRP1 LRP6 LRP5 ALK

1.16e-0449964IPR002172
DomainLDLa

LRP1 LRP6 LRP5 ALK

1.16e-0449964SM00192
DomainDUF1908

MAST4 MAST1

1.56e-044962PF08926
DomainMA_Ser/Thr_Kinase_dom

MAST4 MAST1

1.56e-044962IPR015022
DomainProt_kin_PKC_delta

PRKCE PRKCH

1.56e-044962IPR014376
DomainMAST_pre-PK_dom

MAST4 MAST1

1.56e-044962IPR023142
Domain-

MAST4 MAST1

1.56e-0449621.20.1480.20
DomainUDPGT

UGT2A1 UGT2B15 UGT2B17

1.64e-0421963PF00201
DomainUDPGT

UGT2A1 UGT2B15 UGT2B17

1.64e-0421963PS00375
DomainUDP_glucos_trans

UGT2A1 UGT2B15 UGT2B17

1.64e-0421963IPR002213
DomainAGC-kinase_C

MAST4 MAST1 PRKCE PRKCH

1.96e-0456964IPR000961
DomainAGC_KINASE_CTER

MAST4 MAST1 PRKCE PRKCH

1.96e-0456964PS51285
DomainS_TK_X

MAST4 MAST1 PRKCE PRKCH

1.96e-0456964SM00133
DomainPROTEIN_KINASE_ATP

ACVR1B RET MAST4 BTK MAST1 PRKCE PRKCH EIF2AK4 ALK

5.92e-04459969PS00107
DomainPH-BEACH_dom

NBEA WDFY4

7.17e-048962IPR023362
Domain-

NBEA WDFY4

7.17e-0489622.30.29.40
DomainPH_BEACH

NBEA WDFY4

7.17e-048962PS51783
DomainBEACH_dom

NBEA WDFY4

9.19e-049962IPR000409
DomainBEACH

NBEA WDFY4

9.19e-049962PS50197
DomainBeach

NBEA WDFY4

9.19e-049962PF02138
Domain-

NBEA WDFY4

9.19e-0499621.10.1540.10
DomainBeach

NBEA WDFY4

9.19e-049962SM01026
DomainProt_kinase_dom

ACVR1B RET MAST4 BTK MAST1 PRKCE PRKCH EIF2AK4 ALK

9.27e-04489969IPR000719
DomainPROTEIN_KINASE_DOM

ACVR1B RET MAST4 BTK MAST1 PRKCE PRKCH EIF2AK4 ALK

9.82e-04493969PS50011
DomainLDLR_class-A_CS

LRP1 LRP6 LRP5

1.13e-0340963IPR023415
DomainPkinase_C

MAST1 PRKCE PRKCH

1.31e-0342963PF00433
DomainLdl_recept_a

LRP1 LRP6 LRP5

1.60e-0345963PF00057
DomainKinase-like_dom

ACVR1B RET MAST4 BTK MAST1 PRKCE PRKCH EIF2AK4 ALK

1.89e-03542969IPR011009
DomainMAM_1

PTPRT ALK

2.99e-0316962PS00740
DomainCarboxyPept-like_regulatory

CPZ TENM4

3.38e-0317962IPR008969
DomainProtein_kinase_ATP_BS

ACVR1B RET BTK PRKCE PRKCH EIF2AK4 ALK

3.40e-03379967IPR017441
DomainMAM

PTPRT ALK

3.79e-0318962PF00629
DomainMAM_dom

PTPRT ALK

3.79e-0318962IPR000998
DomainMAM_2

PTPRT ALK

3.79e-0318962PS50060
DomainApc4_WD40_dom

WDR35 WDR17

4.68e-0320962IPR024977
DomainANAPC4_WD40

WDR35 WDR17

4.68e-0320962PF12894
PathwayREACTOME_GLUCURONIDATION

UGT2A2 UGT2A1 UGT2B15 UGT2B17

5.19e-0624694MM14599
PathwayREACTOME_GLUCURONIDATION

UGT2A2 UGT2A1 UGT2B15 UGT2B17

6.15e-0625694M17787
PathwayWP_GLUCURONIDATION

UGT2A2 UGT2A1 UGT2B15 UGT2B17

6.15e-0625694MM15820
PathwayWP_GLUCURONIDATION

UGT2A2 UGT2A1 UGT2B15 UGT2B17

7.24e-0626694M39404
PathwayKEGG_PENTOSE_AND_GLUCURONATE_INTERCONVERSIONS

GUSB UGT2A1 UGT2B15 UGT2B17

9.85e-0628694M19580
PathwayKEGG_PORPHYRIN_AND_CHLOROPHYLL_METABOLISM

GUSB UGT2A1 UGT2B15 UGT2B17

4.64e-0541694M7399
PathwayREACTOME_ASPIRIN_ADME

UGT2A2 UGT2A1 UGT2B15 UGT2B17

6.16e-0544694M45014
PathwayREACTOME_ASPIRIN_ADME

UGT2A2 UGT2A1 UGT2B15 UGT2B17

6.73e-0545694MM15694
PathwayKEGG_DRUG_METABOLISM_OTHER_ENZYMES

GUSB UGT2A1 UGT2B15 UGT2B17

1.10e-0451694M17726
PathwayKEGG_STARCH_AND_SUCROSE_METABOLISM

GUSB UGT2A1 UGT2B15 UGT2B17

1.19e-0452694M14171
PathwayREACTOME_ANTIGEN_ACTIVATES_B_CELL_RECEPTOR_BCR_LEADING_TO_GENERATION_OF_SECOND_MESSENGERS

IGHV3-7 TRPC1 BTK IGHV3-74

1.28e-0453694MM15716
PathwayREACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS

UGT2A2 UGT2A1 UGT2B15 UGT2B17 GSTO1

1.75e-04107695MM14595
PathwayREACTOME_PREDNISONE_ADME

ABCB1 UGT2B15 UGT2B17

1.85e-0423693MM16639
PathwayREACTOME_DRUG_ADME

UGT2A2 ABCB1 UGT2A1 UGT2B15 UGT2B17

1.91e-04109695M45012
PathwayREACTOME_PHASE_II_CONJUGATION_OF_COMPOUNDS

UGT2A2 UGT2A1 UGT2B15 UGT2B17 GSTO1

1.91e-04109695M18788
PathwayWP_WNTBETACATENIN_SIGNALING_INHIBITORS_IN_CURRENT_AND_PAST_CLINICAL_TRIALS

LRP6 LRP5

2.34e-045692M48304
PathwayKEGG_ASCORBATE_AND_ALDARATE_METABOLISM

UGT2A1 UGT2B15 UGT2B17

2.39e-0425693M605
PathwayREACTOME_DRUG_ADME

UGT2A2 ABCB1 UGT2A1 UGT2B15 UGT2B17

2.88e-04119695MM15692
PathwayKEGG_METABOLISM_OF_XENOBIOTICS_BY_CYTOCHROME_P450

UGT2A1 UGT2B15 UGT2B17 GSTO1

3.78e-0470694M16794
PathwayKEGG_DRUG_METABOLISM_CYTOCHROME_P450

UGT2A1 UGT2B15 UGT2B17 GSTO1

4.21e-0472694M9257
PathwayREACTOME_TRANSPORT_OF_SMALL_MOLECULES

LRRC8E TRPC1 TTYH3 SLC1A5 RYR2 ABCB1 SLC6A6 SLC44A1 LPL SLC28A1 SLC26A11

4.35e-046816911MM14985
PathwayREACTOME_FATTY_ACYL_COA_BIOSYNTHESIS

ELOVL1 HACD4 SLC27A2

5.03e-0432693MM15446
PathwayREACTOME_SIGNALING_BY_RNF43_MUTANTS

LRP6 LRP5

6.49e-048692M27433
PathwayREACTOME_NEGATIVE_REGULATION_OF_TCF_DEPENDENT_SIGNALING_BY_WNT_LIGAND_ANTAGONISTS

LRP6 LRP5

6.49e-048692MM14976
PathwayREACTOME_FATTY_ACYL_COA_BIOSYNTHESIS

ELOVL1 HACD4 SLC27A2

7.74e-0437693M729
PathwayREACTOME_TRANSPORT_OF_SMALL_MOLECULES

LRRC8E TRPC1 TTYH3 SLC1A5 RYR2 ABCB1 SLC6A6 SLC44A1 LPL SLC28A1 SLC26A11

8.31e-047366911M27287
PathwayREACTOME_PREDNISONE_ADME

ABCB1 UGT2B17

1.04e-0310692M46430
PathwayWP_WNT_SIGNALING_AND_PLURIPOTENCY

LRP6 LRP5 PRKCE PRKCH

1.50e-03101694M39387
PathwayWP_WNT_SIGNALING_PATHWAY_AND_PLURIPOTENCY

LRP6 LRP5 PRKCE PRKCH

1.50e-03101694MM15829
Pubmed

Establishment and Dysfunction of the Blood-Brain Barrier.

SLC1A5 ABCB1 SLC6A6 SLC44A1 LRP1

4.58e-0752102526590417
Pubmed

The configuration of the 17-hydroxy group variably influences the glucuronidation of beta-estradiol and epiestradiol by human UDP-glucuronosyltransferases.

UGT2A1 UGT2B15 UGT2B17

1.36e-068102318719240
Pubmed

LRP2 mediates folate uptake in the developing neural tube.

LRP1 LRP6 LRP5

3.97e-0611102324639464
Pubmed

Genetic susceptibility to distinct bladder cancer subphenotypes.

DRD2 APAF1 ALDH1L1 RET ABCB1 LPL LRP6 LRP5 MUTYH

4.35e-06421102919692168
Pubmed

Dissecting molecular differences between Wnt coreceptors LRP5 and LRP6.

LRP6 LRP5

8.52e-062102221887268
Pubmed

Expression of UDP Glucuronosyltransferases 2B15 and 2B17 is associated with methylation status in prostate cancer cells.

UGT2B15 UGT2B17

8.52e-062102232660355
Pubmed

PAR1&2 driven placenta EVT invasion act via LRP5/6 as coreceptors.

LRP6 LRP5

8.52e-062102233136328
Pubmed

The low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor binds and mediates catabolism of bovine milk lipoprotein lipase.

LPL LRP1

8.52e-06210221281473
Pubmed

Activated ALK signals through the ERK-ETV5-RET pathway to drive neuroblastoma oncogenesis.

RET ALK

8.52e-062102229321660
Pubmed

LDL receptor-related proteins 5 and 6 in Wnt/beta-catenin signaling: arrows point the way.

LRP6 LRP5

8.52e-062102215084453
Pubmed

The UDP glucuronosyltransferase gene superfamily: suggested nomenclature based on evolutionary divergence.

UGT2B15 UGT2B17

8.52e-06210221909870
Pubmed

Co-deletion of Lrp5 and Lrp6 in the skeleton severely diminishes bone gain from sclerostin antibody administration.

LRP6 LRP5

8.52e-062102233164872
Pubmed

Androgen glucuronidation: an unexpected target for androgen deprivation therapy, with prognosis and diagnostic implications.

UGT2B15 UGT2B17

8.52e-062102224121496
Pubmed

LRP5/6 directly bind to Frizzled and prevent Frizzled-regulated tumour metastasis.

LRP6 LRP5

8.52e-062102225902418
Pubmed

Novel associations of UDP-glucuronosyltransferase 2B gene variants with prostate cancer risk in a multiethnic study.

UGT2B15 UGT2B17

8.52e-062102224267955
Pubmed

The carboxyl-terminal domain of lipoprotein lipase binds to the low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor (LRP) and mediates binding of normal very low density lipoproteins to LRP.

LPL LRP1

8.52e-06210227510694
Pubmed

Differential expression of the androgen-conjugating UGT2B15 and UGT2B17 enzymes in prostate tumor cells during cancer progression.

UGT2B15 UGT2B17

8.52e-062102222170718
Pubmed

A carboxyl-terminal fragment of lipoprotein lipase binds to the low density lipoprotein receptor-related protein and inhibits lipase-mediated uptake of lipoprotein in cells.

LPL LRP1

8.52e-06210227989348
Pubmed

The involvement of the canonical Wnt-signaling receptor LRP5 and LRP6 gene variants with ADHD and sexual dimorphism: Association study and meta-analysis.

LRP6 LRP5

8.52e-062102230474181
Pubmed

In Adult Skeletal Muscles, the Co-Receptors of Canonical Wnt Signaling, Lrp5 and Lrp6, Determine the Distribution and Size of Fiber Types, and Structure and Function of Neuromuscular Junctions.

LRP6 LRP5

8.52e-062102236552732
Pubmed

MTH1, an 8-oxo-2'-deoxyguanosine triphosphatase, and MYH, a DNA glycosylase, cooperate to inhibit mutations induced by chronic exposure to oxidative stress of ionising radiation.

NUDT1 MUTYH

8.52e-062102228340109
Pubmed

Idiopathic Juvenile Osteoporosis: Clinical Experience from a Single Centre and Screening of LRP5 and LRP6 Genes.

LRP6 LRP5

8.52e-062102225783012
Pubmed

Gene targeting approaches in mice: assessing the roles of LRP5 and LRP6 in osteoblasts.

LRP6 LRP5

8.52e-062102219147944
Pubmed

Decreased BMD and limb deformities in mice carrying mutations in both Lrp5 and Lrp6.

LRP6 LRP5

8.52e-062102215537447
Pubmed

Localization of UDP glucuronosyltransferase gene(s) on mouse chromosome 5.

UGT2B15 UGT2B17

8.52e-06210223105095
Pubmed

UDP-glucuronosyltransferase 2B15 (UGT2B15) and UGT2B17 enzymes are major determinants of the androgen response in prostate cancer LNCaP cells.

UGT2B15 UGT2B17

8.52e-062102217848572
Pubmed

LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin.

LRP6 LRP5

8.52e-062102217335347
Pubmed

Androgen and Estrogen Receptors in Breast Cancer Coregulate Human UDP-Glucuronosyltransferases 2B15 and 2B17.

UGT2B15 UGT2B17

8.52e-062102227496708
Pubmed

The Wnt co-receptor Lrp6 is required for normal mouse mammary gland development.

LRP6 LRP5

8.52e-062102219503830
Pubmed

LRP5-/6 gene polymorphisms and its association with risk of abnormal bone mass in postmenopausal women.

LRP6 LRP5

8.52e-062102237202775
Pubmed

Wnt receptors, bone mass, and fractures: gene-wide association analysis of LRP5 and LRP6 polymorphisms with replication.

LRP6 LRP5

8.52e-062102220926594
Pubmed

Common genetic variation of the low-density lipoprotein receptor-related protein 5 and 6 genes determines fracture risk in elderly white men.

LRP6 LRP5

8.52e-062102216355283
Pubmed

Haemorrhagic snake venom metalloproteases and human ADAMs cleave LRP5/6, which disrupts cell-cell adhesions in vitro and induces haemorrhage in vivo.

LRP6 LRP5

8.52e-062102228425175
Pubmed

The uridine diphosphate glucuronosyltransferase 2B15 D85Y and 2B17 deletion polymorphisms predict the glucuronidation pattern of androgens and fat mass in men.

UGT2B15 UGT2B17

8.52e-062102217698910
Pubmed

Evidence against a human cell-specific role for LRP6 in anthrax toxin entry.

LRP6 LRP5

8.52e-062102218350154
Pubmed

Low density lipoprotein receptor related protein 1 and 6 gene variants and ischaemic stroke risk.

LRP1 LRP6

8.52e-062102226031789
Pubmed

Clinical Phenotype and Relevance of LRP5 and LRP6 Variants in Patients With Early-Onset Osteoporosis (EOOP).

LRP6 LRP5

8.52e-062102233118644
Pubmed

Lack of association of LRP5 and LRP6 polymorphisms with type 2 diabetes mellitus in the Japanese population.

LRP6 LRP5

8.52e-062102218493104
Pubmed

PKCε inhibits isolation and stemness of side population cells via the suppression of ABCB1 transporter and PI3K/Akt, MAPK/ERK signaling in renal cell carcinoma cell line 769P.

ABCB1 PRKCE

8.52e-062102227037060
Pubmed

Lrp5 and Lrp6 are required for maintaining self-renewal and differentiation of hematopoietic stem cells.

LRP6 LRP5

8.52e-062102230668923
Pubmed

Both LRP5 and LRP6 receptors are required to respond to physiological Wnt ligands in mammary epithelial cells and fibroblasts.

LRP6 LRP5

8.52e-062102222433869
Pubmed

Mouse UDP glucuronosyltransferase. cDNA and complete amino acid sequence and regulation.

UGT2B15 UGT2B17

8.52e-06210223117546
Pubmed

Wnt-Lrp5 signaling regulates fatty acid metabolism in the osteoblast.

LRP6 LRP5

8.52e-062102225802278
Pubmed

Increased glutamine catabolism mediates bone anabolism in response to WNT signaling.

LRP5 EIF2AK4

8.52e-062102225562323
Pubmed

miR-218-5p restores sensitivity to gemcitabine through PRKCE/MDR1 axis in gallbladder cancer.

ABCB1 PRKCE

8.52e-062102228492560
Pubmed

Anaplastic Lymphoma Kinase Regulates Internalization of the Dopamine D2 Receptor.

DRD2 ALK

8.52e-062102231734646
Pubmed

IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF-κB Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell.

ABCB1 LRP1

8.52e-062102231771696
Pubmed

The UGT2A1/UGT2A2 locus is associated with COVID-19-related loss of smell or taste.

UGT2A2 UGT2A1

8.52e-062102235039640
Pubmed

Distinct roles of LRP5 and LRP6 in Wnt signaling regulation in the retina.

LRP6 LRP5

8.52e-062102233545636
Pubmed

Rat olfactory bulb and epithelium UDP-glucuronosyltransferase 2A1 (UGT2A1) expression: in situ mRNA localization and quantitative analysis.

UGT2A2 UGT2A1

8.52e-062102211376859
Pubmed

Comprehensive Characterization of Mouse UDP-Glucuronosyltransferase (Ugt) Belonging to the Ugt2b Subfamily: Identification of Ugt2b36 as the Predominant Isoform Involved in Morphine Glucuronidation.

UGT2B15 UGT2B17

8.52e-062102228228532
Pubmed

Six novel missense mutations in the LDL receptor-related protein 5 (LRP5) gene in different conditions with an increased bone density.

LRP6 LRP5

8.52e-062102212579474
Pubmed

Cloning and characterization of a novel human olfactory UDP-glucuronosyltransferase.

UGT2A2 UGT2A1

8.52e-062102210359671
Pubmed

UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?

LPL UGT2B17

8.52e-062102226589911
Pubmed

Cellular specific expression of the androgen-conjugating enzymes UGT2B15 and UGT2B17 in the human prostate epithelium.

UGT2B15 UGT2B17

8.52e-062102215666817
Pubmed

Large-scale proteomics and phosphoproteomics of urinary exosomes.

APAF1 TTYH3 ALDH1L1 NEB ABCB1 SLC44A1 GUSB PRKCH SCIN SLC26A11 GSTO1 ALK SLC27A2

8.86e-0610161021319056867
Pubmed

TGFβ attenuates cartilage extracellular matrix degradation via enhancing FBXO6-mediated MMP14 ubiquitination.

TRHDE B3GALNT2 CD109 SLC1A5 TENM4 LRP1

9.29e-06164102632409323
Pubmed

Structural basis for endosomal trafficking of diverse transmembrane cargos by PX-FERM proteins.

TRPC1 RET PTPRB LRP1 ALK

1.25e-05101102523382219
Pubmed

Blood-Brain Barrier: From Physiology to Disease and Back.

SLC1A5 ABCB1 SLC6A6 SLC44A1 LRP1

1.50e-05105102530280653
Pubmed

PTEN identified as important risk factor of chronic obstructive pulmonary disease.

DRD2 APAF1 ALDH1L1 RET ABCB1 LPL LRP6 LRP5

1.51e-05374102819625176
Pubmed

Fulfilling the promise of personalized medicine? Systematic review and field synopsis of pharmacogenetic studies.

DRD2 F5 ABCB1 LPL UGT2B15

1.72e-05108102519956635
Pubmed

Pathway-based evaluation of 380 candidate genes and lung cancer susceptibility suggests the importance of the cell cycle pathway.

DRD2 APAF1 ALDH1L1 RET ABCB1 LPL LRP6 LRP5

1.73e-05381102818676680
Pubmed

Polymorphisms in innate immunity genes and lung cancer risk in Xuanwei, China.

DRD2 APAF1 ALDH1L1 RET ABCB1 LPL LRP6 LRP5

1.76e-05382102819170196
Pubmed

Mutational signature analysis identifies MUTYH deficiency in colorectal cancers and adrenocortical carcinomas.

NUDT1 MUTYH

2.55e-053102228127763
Pubmed

Catalog of 86 single-nucleotide polymorphisms (SNPs) in three uridine diphosphate glycosyltransferase genes: UGT2A1, UGT2B15, and UGT8.

UGT2A1 UGT2B15

2.55e-053102212376738
Pubmed

ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare.

RET ALK

2.55e-053102226973202
Pubmed

Copy-number variations (CNVs) of the human sex steroid metabolizing genes UGT2B17 and UGT2B28 and their associations with a UGT2B15 functional polymorphism.

UGT2B15 UGT2B17

2.55e-053102219572376
Pubmed

ALK, ROS1 and RET fusions in 1139 lung adenocarcinomas: a comprehensive study of common and fusion pattern-specific clinicopathologic, histologic and cytologic features.

RET ALK

2.55e-053102224629636
Pubmed

[Relationship between genetic polymorphism in hMTH1c.83, hOGG1c.326 and hMYHc.335 and risks of chronic benzene poisoning].

NUDT1 MUTYH

2.55e-053102216600130
Pubmed

Multivesicular GSK3 sequestration upon Wnt signaling is controlled by p120-catenin/cadherin interaction with LRP5/6.

LRP6 LRP5

2.55e-053102224412065
Pubmed

Structural insight into the mechanisms of Wnt signaling antagonism by Dkk.

LRP6 LRP5

2.55e-053102218524778
Pubmed

Canonical wnt signaling in dendritic cells regulates Th1/Th17 responses and suppresses autoimmune neuroinflammation.

LRP6 LRP5

2.55e-053102225710911
Pubmed

Epigenetic regulation of steroid inactivating UDP-glucuronosyltransferases by microRNAs in prostate cancer.

UGT2B15 UGT2B17

2.55e-053102226385605
Pubmed

Opposing Roles of Wnt Inhibitors IGFBP-4 and Dkk1 in Cardiac Ischemia by Differential Targeting of LRP5/6 and β-catenin.

LRP6 LRP5

2.55e-053102227803037
Pubmed

Analysis of the oxidative damage repair genes NUDT1, OGG1, and MUTYH in patients from mismatch repair proficient HNPCC families (MSS-HNPCC).

NUDT1 MUTYH

2.55e-053102221355073
Pubmed

Radiographic osteoarthritis at three joint sites and FRZB, LRP5, and LRP6 polymorphisms in two population-based cohorts.

LRP6 LRP5

2.55e-053102218406176
Pubmed

A phorbol ester receptor/protein kinase, nPKC eta, a new member of the protein kinase C family predominantly expressed in lung and skin.

PRKCE PRKCH

2.55e-05310222266135
Pubmed

Low-density lipoprotein receptor-related protein 1 polymorphism 663 C > T affects clotting factor VIII activity and increases the risk of venous thromboembolism.

F5 LRP1

2.55e-053102217155964
Pubmed

Molecular characterization of inflammatory myofibroblastic tumors with frequent ALK and ROS1 gene fusions and rare novel RET rearrangement.

RET ALK

2.55e-053102225723109
Pubmed

Development of lung adenocarcinomas with exclusive dependence on oncogene fusions.

RET ALK

2.55e-053102225855381
Pubmed

Lrp5 and Lrp6 play compensatory roles in mouse intestinal development.

LRP6 LRP5

2.55e-053102221866564
Pubmed

Highly sensitive fusion detection using plasma cell-free RNA in non-small-cell lung cancers.

RET ALK

2.55e-053102234310819
Pubmed

Identification of new ALK and RET gene fusions from colorectal and lung cancer biopsies.

RET ALK

2.55e-053102222327622
Pubmed

Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.

RET ALK

2.55e-053102227056998
Pubmed

Potential Unreliability of Uncommon ALK, ROS1, and RET Genomic Breakpoints in Predicting the Efficacy of Targeted Therapy in NSCLC.

RET ALK

2.55e-053102233248323
Pubmed

Multidrug resistance proteins in renal cell carcinoma.

ABCB1 LRP1

2.55e-053102219393132
Pubmed

Combined analysis of polymorphism variants in hMTH1, hOGG1 and MUTYH genes on the risk of type 2 diabetes in the Chinese population.

NUDT1 MUTYH

2.55e-053102223396182
Pubmed

Canonical Wnt Signaling in CD11c+ APCs Regulates Microbiota-Induced Inflammation and Immune Cell Homeostasis in the Colon.

LRP6 LRP5

2.55e-053102229602775
Pubmed

8-Oxoguanine causes neurodegeneration during MUTYH-mediated DNA base excision repair.

NUDT1 MUTYH

2.55e-053102223143307
Pubmed

LRP5 in premature adrenarche and in metabolic characteristics of prepubertal children.

LRP6 LRP5

2.55e-053102218721193
Pubmed

Comprehensive analysis of ALK, ROS1 and RET rearrangements in locally advanced rectal cancer.

RET ALK

2.55e-053102233168793
Pubmed

tPA regulates neurite outgrowth by phosphorylation of LRP5/6 in neural progenitor cells.

LRP6 LRP5

2.55e-053102223925701
Pubmed

Development and characterization of multidrug resistant human hepatocarcinoma cell line in nude mice.

ABCB1 LRP1

2.55e-053102217075973
Pubmed

Regulation of Human UGT2B15 and UGT2B17 by miR-376c in Prostate Cancer Cell Lines.

UGT2B15 UGT2B17

2.55e-053102226163549
Pubmed

Germline susceptibility to colorectal cancer due to base-excision repair gene defects.

NUDT1 MUTYH

2.55e-053102215931596
Pubmed

The structural basis of DKK-mediated inhibition of Wnt/LRP signaling.

LRP6 LRP5

2.55e-053102222589387
Pubmed

Forkhead box protein A1 regulates UDP-glucuronosyltransferase 2B15 gene transcription in LNCaP prostate cancer cells.

UGT2B15 UGT2B17

2.55e-053102220736324
Pubmed

Wnt co-receptor LRP5/6 overexpression confers protection against hydrogen peroxide-induced neurotoxicity and reduces tau phosphorylation in SH-SY5Y cells.

LRP6 LRP5

2.55e-053102225959626
Pubmed

Mutational analysis of OGG1, MYH, MTH1 in FAP, HNPCC and sporadic colorectal cancer patients: R154H OGG1 polymorphism is associated with sporadic colorectal cancer patients.

NUDT1 MUTYH

2.55e-053102215449173
Pubmed

Two structural and functional domains of MESD required for proper folding and trafficking of LRP5/6.

LRP6 LRP5

2.55e-053102221397183
Cytoband4q13

UGT2A1 UGT2B15 UGT2B17

4.75e-061510234q13
Cytoband12q15-q21

TRHDE PTPRB

1.46e-053102212q15-q21
Cytoband7q21.12

ELAPOR2 ABCB1

1.36e-04810227q21.12
CytobandEnsembl 112 genes in cytogenetic band chr4q13

UGT2A2 UGT2A1 UGT2B15 UGT2B17

4.31e-041571024chr4q13
Cytoband7p22

TTYH3 NUDT1

9.05e-042010227p22
Cytoband14q32.33

IGHV3-7 IGHV5-10-1 IGHV5-51 IGHV3-74

1.72e-03228102414q32.33
GeneFamilyUDP glucuronosyltransferases

UGT2A2 UGT2A1 UGT2B15 UGT2B17

5.73e-0632674363
GeneFamilyLow density lipoprotein receptors

LRP1 LRP6 LRP5

1.35e-0513673634
GeneFamilyWD repeat domain containing|BEACH domain containing

NBEA WDFY4

4.79e-0496721230
GeneFamilyC2 domain containing protein kinases

PRKCE PRKCH

5.97e-0410672835
GeneFamilySolute carriers

SLC1A5 SLC6A6 SLC44A1 SLC16A4 SLC28A1 SLC26A11 SLC27A2

6.34e-04395677752
GeneFamilyProtein tyrosine phosphatases, receptor type

PTPRT PTPRB

2.71e-0321672813
GeneFamilyWD repeat domain containing

APAF1 NBEA WDFY4 WDR35 WDR17

2.86e-03262675362
GeneFamilyImmunoglobulin heavy locus at 14q32.33

IGHV3-7 IGHV5-10-1 IGHV5-51 IGHV3-74

5.11e-03187674349
CoexpressionMEBARKI_HCC_PROGENITOR_FZD8CRD_DN

DOCK4 DPT DCDC1 ADAMTS13 ALDH1L1 NEB F5 PTGFR ABCB1 SLC28A1 ACMSD

1.63e-0645910111M38993
CoexpressionGSE6259_33D1_POS_DC_VS_CD8_TCELL_DN

TMEM50A DDX60 RTTN HACD4 SCN7A LRP6

1.42e-051351016M6759
CoexpressionMANNO_MIDBRAIN_NEUROTYPES_HNBGABA

TRHDE DOCK4 TRIM58 NBEA ACVR1B WDFY4 PTPRT RYR2 FRMD4A TENM4 SCN7A MAST1

1.70e-0570310112M39070
CoexpressionMARTIN_NFKB_TARGETS_UP

TTYH3 ABCB1 SLC16A4 PRKCE

2.28e-05431014M1325
CoexpressionMARTIN_NFKB_TARGETS_UP

TTYH3 ABCB1 SLC16A4 PRKCE

2.99e-05461014MM552
CoexpressionLEE_BMP2_TARGETS_UP

DPT SCRN1 HACD4 CPZ F5 ABCB1 PTPRB DNAJC28 LPL SCN7A LRP1 GSTO1

4.68e-0578010112M2324
CoexpressionLEE_BMP2_TARGETS_UP

DPT SCRN1 HACD4 CPZ F5 ABCB1 PTPRB DNAJC28 LPL SCN7A LRP1 GSTO1

6.33e-0580510112MM1067
ToppCellCOVID-19-kidney-Distal_Epi_Doublet_(PCT)|COVID-19 / Disease (COVID-19 only), tissue and cell type

TRHDE ALDH1L1 ABCB1 SLC28A1 ACMSD SCIN SLC27A2

2.11e-0718210279d67717a6e13bcb54c1297a3e4e3abf4e51628a3
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_1_/_Segment_2|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

RTTN TTYH3 ALDH1L1 MAST4 SLC28A1 ACMSD SLC27A2

2.19e-071831027facd6dbe0851b537d70a899ac7485714ab27d071
ToppCellChildren_(3_yrs)-Immune-alveolar_macrophage_(MARCO_positive)-D032|Children_(3_yrs) / Lineage, Cell type, age group and donor

TRHDE WDFY4 SLC6A6 FRMD4A TENM4 LPL ALK

2.63e-071881027d7a9fb5b021e127b8d927658a55a71098d513b5c
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Adaptive_/_Maladaptive_/_Repairing_Proximal_Tubule_Epithelial_Cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

DCDC1 ABCB1 SLC6A6 SLC16A4 SLC28A1 ACMSD SLC27A2

2.72e-07189102728b502611829e4a24caff2562545c7db97686099
ToppCellfacs-Lung-nan-3m-Endothelial-endothelial_cell_of_lung|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

STARD8 TTYH3 PTPRB SCN7A LRP5 PRKCE PRKCH

3.25e-071941027f159ef8541d75a4e98468947f231bb463bec922c
ToppCellBronchial-NucSeq-Immune_Myeloid-Macrophage_other-Macro_CHIT1|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

TMEM150B TTYH3 WDFY4 FRMD4A BTK LRP1 SLC26A11

3.73e-0719810270b41b3d6c2db795320e8b65d40d85fb8b618cc34
ToppCellLPS-antiTNF-Stromal_mesenchymal-Myocytic-Pericyte_2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

DRD2 RYR2 FRMD4A LPL LRP6 ALK

1.68e-061571026bfec34182f052cf1c0d847ba53ea335d4d1190de
ToppCellTCGA-Adrenal-Primary_Tumor-Pheochromocytoma-Pheochromocytoma-1|TCGA-Adrenal / Sample_Type by Project: Shred V9

TRHDE DRD2 NBEA RET PRKCE ALK

3.58e-061791026431e1b29015ec817f778499106d24b19cfc825ae
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ALDH1L1 TENM4 MAST4 SLC28A1 ACMSD SLC27A2

4.19e-0618410269434731f651820b05335085582960f08fbf895de
ToppCellControl-Endothelial-Endothelial-Vein|Control / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

F5 ABCB1 SLC6A6 PTPRB PRKCH RASSF9

4.46e-06186102692092f11ecce22c14f244e42c499af0822977e6f
ToppCellfacs-Lung-nan-3m-Endothelial-Capillary_endothelial_cell|Lung / Lung_Trachea - method, tissue, subtissue, age, lineage, cell ontology and free annotation

FRMD4A PTPRB LPL SCN7A LRP5 PRKCH

5.35e-0619210264bab9754cfd8b9c2d7cc1490e8a29f58c3c26f6c
ToppCellrenal_papilla_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

DOCK4 CD109 ABCB1 SLC6A6 PTPRB PRKCH

5.35e-0619210263259cb89d6bcf0a3c6ff1f64d85e8a1f54124e91
ToppCellAdult-Immune-alveolar_macrophage_(MARCO_positive)-D122|Adult / Lineage, Cell type, age group and donor

TMEM150B WDFY4 SLC6A6 FRMD4A LRP1 PRKCE

5.51e-061931026cc1b6d3bf56e4a88f6fe23dd036a83cf5538c958
ToppCellLPS-antiTNF-Endothelial-Endothelial-Gen_Cap|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

CD109 ABCB1 PTPRB MAST4 PRKCE PRKCH

5.51e-0619310266e1982d089a9de628e6006d23ff78a223fbd9f47
ToppCellFetal_29-31_weeks-Mesenchymal-matrix_fibroblast_1_cell|Fetal_29-31_weeks / Lineage, Cell type, age group and donor

TRHDE DOCK4 RYR2 FRMD4A LPL SCN7A

5.68e-061941026011e14d9ed1393275f892060e7708ffadcd0767f
ToppCellChildren_(3_yrs)-Immune-alveolar_macrophage_(MARCO_positive)|Children_(3_yrs) / Lineage, Cell type, age group and donor

WDFY4 SLC6A6 FRMD4A LPL LRP1 GSTO1

5.68e-06194102669cf7c989ac355c459db13f9d4267b55adc3c174
ToppCellLPS_only-Endothelial|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

CD109 ABCB1 PTPRB MAST4 PRKCE PRKCH

5.68e-06194102658f069efdefa0366033764446b9d6ffd4a17807e
ToppCellLPS_only-Endothelial-Endothelial|LPS_only / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

CD109 ABCB1 PTPRB MAST4 PRKCE PRKCH

5.68e-061941026bfd92ec75facb0ba55c31e5f2e089d983b3d0169
ToppCellbackground-Endothelial_cells|background / Sample and Cell Type and Tumor Cluster (all cells)

DOCK4 PTPRT PTPRB MAST4 PRKCE PRKCH

6.02e-061961026e6fb0bfab1779ec64a8c35d01519eaafbf62e977
ToppCellFibroblasts-DKK3+_Fibroblasts|Fibroblasts / Immune cells in Rheumatoid Arthritis Joint Synovial Tissues

DPT CD109 SCRN1 HACD4 F5 SLC6A6

6.02e-06196102624d64b67aa9b0e8215ad06f9101c1314b3483620
ToppCellkidney_cells-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

ALDH1L1 SLC16A4 UGT2A1 SLC28A1 ACMSD SLC27A2

6.02e-0619610264ebcaac758ed01d918de9c1cd383a84457b615f3
ToppCellTracheal-10x5prime-Immune_Lymphocytic-B-B_cell|10x5prime / Cell types per location group and 10X technology with lineage, and cell group designations

IGHV3-7 WDFY4 BTK UGT2B17 IGHV5-51 IGHV3-74

6.20e-0619710260e56255862fed099e771ebd2529393dc5a3641ba
ToppCellsaliva-Severe-critical_progression_d12-22_no-steroids|saliva / Compartment, severity and other cell annotations on 10x 3' data (130k)

DOCK4 OTOA TTYH3 LPL LRP1 GSTO1

6.20e-061971026c747d05bb032abf8dad46ff6f4d1951bbe64b3b4
ToppCellParenchymal-NucSeq-Immune_Myeloid-Macrophage_alveolar-Macro_alveolar|NucSeq / Cell types per location group and 10X technology with lineage, and cell group designations

TMEM150B WDFY4 FRMD4A LPL BTK LRP1

6.38e-0619810260baeb8e2c199ff10bb5c829c523546af3c9227c1
ToppCellIPF-Myeloid-Macrophage|Myeloid / Disease state, Lineage and Cell class

DOCK4 OTOA CD109 TTYH3 SLC44A1 SLC26A11

6.57e-0619910263c2b362d5e824e1a04830e70352f8818de984174
ToppCellmoderate-Myeloid-Non-resident_Macrophage|moderate / Severity, Lineage and Cell class of Nasopharyngeal (NS) Samples from Patients and Controls

DOCK4 CD109 TTYH3 LPL LRP1 GSTO1

6.57e-061991026614c1e788d89310e78984241977941beed8d12dc
ToppCellLPS_IL1RA_TNF-Endothelial-Endothelial-Artery|LPS_IL1RA_TNF / Treatment groups by lineage, cell group, cell type

CD109 F5 PTPRB MAST4 LPL PRKCH

6.76e-06200102677ae679c35d3b9e2b620f34129f3a8d47e922c65
ToppCellLPS_IL1RA-Endothelial-Endothelial-Artery|LPS_IL1RA / Treatment groups by lineage, cell group, cell type

CD109 F5 PTPRB MAST4 LPL PRKCH

6.76e-062001026ac9ead34afa14067171833f5c277eaf06db7b02e
ToppCellLPS_only-Mesenchymal_myocytic-Pericyte-Pericyte_2|LPS_only / Treatment groups by lineage, cell group, cell type

NBEA HACD4 RYR2 FRMD4A LPL WDR17

6.76e-06200102669edc375d85689300d1dbc1217fedc40063ecdcb
ToppCellLPS_only-Endothelial-Endothelial-Artery|LPS_only / Treatment groups by lineage, cell group, cell type

CD109 F5 PTPRB MAST4 LPL PRKCH

6.76e-062001026b17eb1587ca86c3d40515128a00a8d8fd787fccf
ToppCell3'-GW_trimst-1.5-LargeIntestine-Neuronal-neuron_precursor|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TRHDE DRD2 RET TAS1R1 WDR17

3.68e-05163102599cf60dc87f7ce288553091bffcd85109a02bd8f
ToppCell3'-GW_trimst-1.5-LargeIntestine-Neuronal-neuron_precursor-Neuroblast|GW_trimst-1.5 / Celltypes from developing, pediatric, Crohn's, & adult GI tract

TRHDE DRD2 RET TAS1R1 WDR17

3.68e-051631025510c0af66e82c5a8cf8edd0547dae4018a87dbbf
ToppCellLPS-antiTNF-Endothelial-Mes-Like-Alv_Cap|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

HACD4 COQ3 ABCB1 MUTYH TMEM50B

4.02e-05166102594a00edf66d54bc5f7343daea700ca26cf38fd90
ToppCellASK428-Immune-Mast_cell|Immune / Donor, Lineage and Cell class of Lung cells from Dropseq

NBEA SLC44A1 PTPRB BTK SCIN

4.25e-051681025c399fcb4d1d0be48026c2ecabc34a5935e7adf73
ToppCellTCGA-Liver-Primary_Tumor-Hepatocellular_Carcinoma-Hepatocellular_Carcinoma-6|TCGA-Liver / Sample_Type by Project: Shred V9

HACD4 CPZ SCN7A PRKCH WDR17

4.37e-051691025e992530776cab922d0360b275fb9cb8bd0017b06
ToppCellPND10-Mesenchymal-Mesenchymal_structural-Fibroblastic-AF2-AF2_prolif|PND10 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

TMEM150B SCRN1 PTGFR DNAJC28 TMEM184C

4.50e-0517010258465c3069bbc08705d070927e712b6bc85ac7c5b
ToppCellTCGA-Brain-Primary_Tumor-Low_Grade_Glioma-Astrocytoma-10|TCGA-Brain / Sample_Type by Project: Shred V9

CD109 WDFY4 UGT2B17 DLEC1 RASSF9

4.63e-05171102574be8d3bf6b99e2d734635a8b1a7c41e8c596959
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_1_/_Segment_2|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

TMEM150B TTYH3 SLC28A1 ACMSD SLC27A2

4.63e-051711025f5014e3c387fe3118944af392abe10d6b9b0abab
ToppCellCOVID-19-Heart-T_cell|COVID-19 / Disease (COVID-19 only), tissue and cell type

TRIM58 NEB PTPRT UGT2B15 ALK

4.63e-051711025b2e753e811a7639956994609f73efcdb62d04f82
ToppCell5'-Parenchyma_lung-Immune_Myeloid-Myeloid_macrophage-alveolar_macrophage-Alveolar_macrophages-Alveolar_macrophages_L.1.6.0.0|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

TRHDE TMEM150B WDFY4 LPL LRP1

4.76e-051721025c8ea80042faf923b08ff03d73100533d521d73ef
ToppCellkidney_cells-Adult_normal_reference-Epithelial-Distal_tubule_epithelial_cell-kidney_distal_convoluted_tubule_epithelial_cell-Distal_Convoluted_Tubule_Cell_Type_1|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

PTGFR FRMD4A CNOT6L LPL LRP6

4.89e-0517310250c74bdb40e635d906fd180412c23bf7fed61621e
ToppCellPND14-Immune-Immune_Myeloid-Monocytic-Macrophage-AM-AM_prolif|PND14 / Age_group by Lineage, Lineage_subclass, Cell_type, subtypes-by-prolif

DOCK4 WDFY4 FAM151B FRMD4A LRP1

5.30e-051761025450c25ec5eeb65425f904e0a25aaafdf5682ef9c
ToppCell3'-Broncho-tracheal-Epithelial-Epithelial_transtional-secretory-nasal_mucosa_goblet_cell-Goblet_(nasal)-Goblet_(nasal)_L.0.2.2.1|3' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

DCDC1 NBEA PTPRT SCIN SLC27A2

5.30e-051761025dee780cfa85234a7cd7bf440b66b84cec959893e
ToppCellRV-11._Adipocyte|World / Chamber and Cluster_Paper

TRHDE ALDH1L1 FRMD4A TENM4 LPL

5.45e-051771025f0edf04930692418953e4f00a917257804ec0ffd
ToppCell10x3'2.3-week_12-13-Mesenchymal_myocytic-stroma-muscle_stem_cell|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

TRHDE DPT IGHV3-7 PTGFR TENM4

5.60e-0517810258f31b3fac51591f7f2bcb898c07708b3e9f93a16
ToppCellRV-11._Adipocyte|RV / Chamber and Cluster_Paper

TRHDE ALDH1L1 FRMD4A TENM4 LPL

5.60e-051781025278bbea5cf8f0589f71675c7a3d00679391b5253
ToppCell368C-Myeloid-Macrophage-SPP1+_Macrophage_3|368C / Donor, Lineage, Cell class and subclass (all cells)

SART3 TTYH3 WDFY4 LPL SCIN

5.60e-051781025536a601abcc60867949ea06e9aafb6c7b799b56b
ToppCelldroplet-Liver-LIVER_NPC-30m-Endothelial-nan|Liver / Large_Intestine_Pancreas_Liver - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DOCK4 TRPC1 RINT1 PTPRB MAST4

5.75e-051791025025d414ec88d5680d99c8173e70ee3bb0b694f74
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

PTPRT MAST4 SLC28A1 ACMSD SLC27A2

5.75e-051791025d1ef7e1cb00336118e387b47f4f8120f53584391
ToppCellCOVID-19-kidney-PCT-S2|COVID-19 / Disease (COVID-19 only), tissue and cell type

ALDH1L1 ABCB1 SLC28A1 ACMSD SLC27A2

5.90e-051801025358923e4228035a3e90e2957392089219e90dcd7
ToppCellrenal_medulla_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_1_/_Segment_2|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

TMEM150B MAST4 SLC28A1 ACMSD SLC27A2

5.90e-0518010251363b3254470f6ff98630d1df83a1bdbacc137e0
ToppCellRA-11._Adipocyte|RA / Chamber and Cluster_Paper

TRHDE ALDH1L1 FRMD4A TENM4 LPL

5.90e-051801025d48a3d27357f7d184132a6805950f93080146b59
ToppCellCOVID-19-kidney-tDL|COVID-19 / Disease (COVID-19 only), tissue and cell type

ALDH1L1 ABCB1 SLC28A1 ACMSD SLC27A2

5.90e-051801025864c895b5eaedefae86f5829fa344f7b686fb59f
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

MAST4 SLC16A4 SLC28A1 ACMSD SLC27A2

6.06e-0518110259542c19edc9bd2cba68c01c2a8407705398e3011
ToppCell10x3'2.3-week_12-13-Mesenchymal_myocytic|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

TRHDE DPT PTGFR TENM4 SCIN

6.06e-05181102547dce04db3392333eb2f7b9b24c32e6740d2d02f
ToppCellControl-Myeloid-Alveolar_macrophages|Control / group, cell type (main and fine annotations)

TRHDE WDFY4 FRMD4A LPL LRP1

6.06e-0518110258d2102c8c86c59a82610f26f90946b290552e666
ToppCell10x3'2.3-week_12-13-Mesenchymal_myocytic-stroma|week_12-13 / cell types per 3 fetal stages;per 3',per 5'

TRHDE DPT PTGFR TENM4 SCIN

6.06e-05181102519103221c3a5a16b16378348004b2c50caee4f01
ToppCellrenal_medulla_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

MAST4 SLC16A4 SLC28A1 ACMSD SLC27A2

6.06e-0518110258f04f8cac5d705dc5f6cf6f4516d6e45b0aa4ae5
ToppCellBALF-PFMC-Severe-critical_progression_d12-22_with-steroid-Myeloid-Monocytic-Nonclassical_Monocyte|Severe-critical_progression_d12-22_with-steroid / Compartment, severity and other cell annotations on 10x 3' data (130k)

DOCK4 OTOA STARD8 LPL GSTO1

6.38e-05183102536b194e366a14ebc4df187bf31c902be3797bfcc
ToppCellLA-11._Adipocyte|World / Chamber and Cluster_Paper

TRHDE ALDH1L1 FRMD4A TENM4 LPL

6.38e-051831025b177be283e1553fb1f69a346f1ba79ad00297fa2
ToppCellLA-11._Adipocyte|LA / Chamber and Cluster_Paper

TRHDE ALDH1L1 FRMD4A TENM4 LPL

6.38e-0518310253f9011976782fa8aa95cdd6f00f07a91094d411b
ToppCellkidney_cells-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ALDH1L1 UGT2A1 SLC28A1 ACMSD SLC27A2

6.38e-051831025d73cac83cde82665f110baad7cf28db75f9ffe52
ToppCellCOVID-19-kidney-PCT-S1|COVID-19 / Disease (COVID-19 only), tissue and cell type

TRHDE ALDH1L1 SLC28A1 ACMSD SLC27A2

6.38e-0518310256878d14026c3df6aa12e45dfad94b32fa9d9b0b7
ToppCellLPS-IL1RA+antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|LPS-IL1RA+antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

HACD4 RYR2 FRMD4A LPL WDR17

6.38e-0518310258a799807fbf24456a9811e0c64068187940a2f71
ToppCell3'_v3-blood-Lymphocytic_B_plasma|blood / Manually curated celltypes from each tissue

IGHV3-7 TAS1R1 UGT2B17 IGHV5-51 IGHV3-74

6.38e-0518310252477183a290b2c45b6fa091ed76969a3826fe3d9
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-thymocyte|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

TRHDE OTOA NEB RYR2 TENM4

6.55e-0518410252cbed6462fea2622871bb7e49b0df3d984239281
ToppCellLPS-antiTNF-Stromal_mesenchymal-Lung_smooth_muscle-Pericyte_2|LPS-antiTNF / V2 postpublication: Rhesus Genome Updated; Treatment groups by lineage, cell_type_level1, cell_type_level2

RYR2 FRMD4A LPL LRP6 WDR17

6.55e-051841025689a8af81a79a4bb3123cfa01958c953eab5de98
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

TRHDE OTOA NEB RYR2 TENM4

6.55e-051841025ea7a7e2bac46d4d2c31a5d576b38a032b5335062
ToppCellfacs-Thymus-Thymus_Epithelium-18m-Lymphocytic-proliferating_thymocyte;_DN_to_DP_transition,_dividing_(some_are_Cd8+/_Cd4+,_some_undergoing_VDJ_recombination)|Thymus / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

TRHDE OTOA NEB RYR2 TENM4

6.55e-0518410252b19a8c5f823e00812908b23e66bb4e563278aff
ToppCellMild_COVID-19-Myeloid-MoAM4|Mild_COVID-19 / Disease group,lineage and cell class （2021.01.30）

OTOA TRIM58 TTYH3 SCIN SLC26A11

6.55e-05184102563ef6ba6ac33c3032735008ce3b411636ab3c395
ToppCellCOVID-19-kidney-PCT-S1/S2|kidney / Disease (COVID-19 only), tissue and cell type

TTYH3 MAST4 SLC28A1 ACMSD SLC27A2

6.55e-051841025dc71f22583fc54b89b242cbb602f4bbe86f576ec
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

TTYH3 ALDH1L1 SLC28A1 ACMSD SLC27A2

6.89e-051861025a417e1e21313a7e05951038cdef5ac672a9f727c
ToppCellfacs-Heart-LA-24m-Mesenchymal|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DPT SLC1A5 SCN7A LRP1 SCIN

6.89e-051861025ed0a91f47e77fe21d4c7678d0f2a7c5f97d63dda
ToppCell390C-Lymphocytic-CD4_T-cell-Treg_cell_3|Lymphocytic / Donor, Lineage, Cell class and subclass (all cells)

DPT COQ3 WDFY4 MAST4 WDR35

6.89e-05186102574eb69a52090f9e2426a47e03a1c478ee0cfec18
ToppCellrenal_cortex_nuclei-CKD+DKD_normotensive-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell-Proximal_Tubule_Epithelial_Cell_Segment_3|CKD+DKD_normotensive / Celltypes from Cells and Nuclei per compartment and clinical group

PTPRT SLC6A6 TENM4 MAST4 SLC28A1

6.89e-051861025b1edc341d6684b347dc9e21b34f62f51d095d735
ToppCell10x5'-Lung-Mast|Lung / Manually curated celltypes from each tissue

NBEA SLC44A1 PTPRB MAST4 SCIN

7.07e-051871025f8ac5ca5cbe9c6f3d8c0fffc20fe08ca1aea43c0
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

TTYH3 ALDH1L1 SLC28A1 ACMSD SLC27A2

7.07e-0518710251b82920588f9e26ef1db244d452736d75fcfd342
ToppCellfacs-Heart-LA-24m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DPT SLC1A5 SCN7A LRP1 SCIN

7.07e-051871025f3ef3f5a761f8306edc39bf16e76e44aae6fa7f6
ToppCell10x5'-Lung-Mast-Mast_cells|Lung / Manually curated celltypes from each tissue

NBEA SLC44A1 PTPRB MAST4 SCIN

7.07e-051871025da275d2c774b3e6a8ed77f777dd0676ecf2ddd2c
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ALDH1L1 MAST4 SLC28A1 ACMSD SLC27A2

7.07e-051871025dcf6475ece5b34d9d58a0d1f51c18acedb19c119
ToppCellCOVID-19-kidney-tDL|kidney / Disease (COVID-19 only), tissue and cell type

MAST4 SLC16A4 SLC28A1 ACMSD SLC27A2

7.07e-051871025d35d27ca3c0e65f92f4508e1cb98a743f44fdcdf
ToppCellfacs-Heart-LA-24m-Mesenchymal-fibroblast_of_cardiac_tissue|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DPT SLC1A5 SCN7A LRP1 SCIN

7.07e-0518710251669df899b1759c338ffce196fe009840123cfcd
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Epithelial-Proximal_tubule_epithelial_cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

ALDH1L1 MAST4 SLC28A1 ACMSD SLC27A2

7.07e-051871025f1356273bd3587b6883295edf15cb9cdb706c057
ToppCellCOVID-19-kidney|COVID-19 / Disease (COVID-19 only), tissue and cell type

TRHDE ALDH1L1 SLC28A1 ACMSD SCIN

7.07e-051871025d23aae9419d460b78b1d4092d7acd9108a47cfbe
ToppCellCOVID-19-kidney-Mito-rich_PCT|kidney / Disease (COVID-19 only), tissue and cell type

TTYH3 MAST4 SLC28A1 ACMSD SLC27A2

7.07e-051871025738ec2611b4be6a08eedad16b57fba84e1f11fef
ToppCellrenal_medulla_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

TTYH3 ALDH1L1 SLC28A1 ACMSD SLC27A2

7.07e-051871025c1e4c0345f9bfa0538730bad5ff3fa5240168b25
ToppCellCOVID-19-kidney-Stressed_PCT|kidney / Disease (COVID-19 only), tissue and cell type

ABCB1 MAST4 SLC28A1 ACMSD SLC27A2

7.07e-051871025acd305475f3609800af0d7bc68d83ef41228080b
ToppCelldroplet-Heart-HEART_(LV+RV_ONLY)-30m-Endothelial-endothelial_cell_of_coronary_artery|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC6A6 PTPRB LPL PRKCH RASSF9

7.25e-0518810258a87daf2851d9404df7c36f279db599574b47c69
ToppCelldroplet-Heart-HEART_(LV+RV_ONLY)-30m-Endothelial|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC6A6 PTPRB LPL PRKCH RASSF9

7.25e-0518810250f426cca2ad7671fed9c6d2aa09f6a8627a518cd
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

TTYH3 MAST4 SLC28A1 ACMSD SLC27A2

7.25e-051881025f3edcefeef2ce19086032d98b243c02a6d542b38
ToppCellRA-11._Adipocyte|World / Chamber and Cluster_Paper

TRHDE ALDH1L1 FRMD4A TENM4 LPL

7.25e-0518810254dac9d636e5cad4cda540b93d4bfed6b5732c880
ToppCellrenal_cortex_nuclei-Hypertensive_with+without-CKD-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell|Hypertensive_with+without-CKD / Celltypes from Cells and Nuclei per compartment and clinical group

TTYH3 MAST4 SLC28A1 ACMSD SLC27A2

7.25e-0518810250792432cd4c564dea1102241ea9884f7ced7658c
ToppCelldroplet-Heart-HEART_(LV+RV_ONLY)-30m-Endothelial-coronary_vascular_endothelial_cell|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC6A6 PTPRB LPL PRKCH RASSF9

7.25e-051881025aec7485f1a9412bd3a62b70c801cb7f8dcca232d
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell-kidney_proximal_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

TTYH3 MAST4 SLC28A1 ACMSD SLC27A2

7.43e-051891025204ab61ae606b2d9be0cb6bf6a83a011740693a8
ToppCellrenal_cortex_nuclei-Renal_AKI_(acute_kidney_injury)-Epithelial-Proximal_tubule_epithelial_cell|Renal_AKI_(acute_kidney_injury) / Celltypes from Cells and Nuclei per compartment and clinical group

TTYH3 MAST4 SLC28A1 ACMSD SLC27A2

7.43e-05189102513fd07cc408a9486f61a7b2c3a132c52d14b438d
ToppCellrenal_cortex_nuclei-Adult_normal_reference-Endothelial-blood_vessel_endothelial_cell_of_kidney-arteriolar_vasa-recta_endothelial-Afferent_/_Efferent_Arteriole_Endothelial_Cell|Adult_normal_reference / Celltypes from Cells and Nuclei per compartment and clinical group

DOCK4 CD109 SLC6A6 PTPRB PRKCH

7.62e-051901025bf9bc57a605c7e3979bc4f7260e6fb92c3eb8690
ToppCellBAL-Severe-Myeloid-TRAM-TRAM1-|Severe / Location, Disease Group, Cell group, Cell class and sub_cluster (2021.03.01)

TRHDE HACD4 FRMD4A LPL LRP1

7.62e-0519010250eef5a8bd88ef8a25a67d9dd522d9472fa4b3d2f
ToppCellCOPD-Myeloid-Macrophage_Alveolar|COPD / Disease state, Lineage and Cell class

TRHDE FRMD4A LPL LRP1 GSTO1

7.62e-051901025006e31606d637033bc81333816ee332773d36b08
ToppCellfacs-Heart-RV-3m-Endothelial-endothelial_cell_of_coronary_artery|Heart / Tongue_Heart_Limb_Muscle_Aorta_Diaphragm - method, tissue, subtissue, age, lineage, cell ontology and free annotation

SLC6A6 PTPRB LPL PRKCH RASSF9

7.62e-05190102589d1d686cc683206534e2157554d7d0df5d53497
ToppCellControl-Endothelial-VE_Capillary_B|Endothelial / Disease state, Lineage and Cell class

DOCK4 CD109 PTPRB MAST4 PRKCE

7.62e-0519010257f3f419fffe02934b6f27b697f7a6401072491ed
Drugpheophytin

TMEM50A F5 ABCB1 GUSB UGT2A1 UGT2B15 UGT2B17 PRKCE PRKCH GSTO1 ALK

4.02e-082849811CID000000250
DrugAA-149

SLC1A5 ABCB1 GUSB

7.68e-075983CID000005536
DrugT4-G

GUSB UGT2A1 UGT2B15 UGT2B17

1.19e-0619984CID000152424
Drugsodium cholate

ABCB1 SLC6A6 GUSB LPL UGT2A1 SLC28A1 LRP1 UGT2B15 UGT2B17 LRP6 SLC27A2

1.48e-064089811CID000000303
Drugclozapine; Up 200; 10uM; MCF7; HT_HG-U133A

DRD2 ADAMTS13 ACVR1B NEB RYR2 SLC6A6 SLC44A1 MED12

2.20e-061979886988_UP
DrugTiratricol, 3,3',5-triiodothyroacetic acid [51-24-1]; Up 200; 6.4uM; MCF7; HT_HG-U133A

ALDH1L1 ACVR1B NEB FRMD4A TENM4 LRP5 PRKCE TTC33

2.29e-061989887011_UP
Drugestradiol-3-glucuronide

GUSB UGT2A1 UGT2B15 UGT2B17

2.68e-0623984CID000066651
DrugDITPA

DPT RET RYR2 MED12

3.21e-0624984CID000160565
DrugSN-38G

ABCB1 GUSB UGT2A1 UGT2B15 UGT2B17

5.55e-0659985CID000443154
DrugL-idaro-1,4-lactone

GUSB UGT2A1 UGT2B15 UGT2B17

6.10e-0628984CID000078997
Drug7-hydroxycoumarin glucuronide

GUSB UGT2A1 UGT2B15 UGT2B17

7.06e-0629984CID000125641
DrugMeldola

GUSB UGT2A1 UGT2B15 UGT2B17 ALG1

1.12e-0568985CID000081507
DrugAdenosine triphosphate

APAF1 ACVR1B ABCB1 ALK

1.20e-0533984DB00171
DrugAC1Q6OQG

GUSB UGT2A1 UGT2B15 UGT2B17

1.20e-0533984CID000009686
DrugAC1NOWCJ

GUSB UGT2A1 UGT2B15 UGT2B17

1.53e-0535984CID005120112
Drug3-[(3S,5R,10S,13R,14S,17R)-3-[(2S,4R,5R,6S)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]-2H-furan-5-one

GUSB UGT2A1 UGT2B15 UGT2B17

1.53e-0535984CID010436171
DrugD 251

GUSB LPL

1.83e-052982CID003048154
Druggalangin

ABCB1 GUSB UGT2B15 UGT2B17

1.91e-0537984CID005281616
Drugdansylphosphatidylethanolamine

RET F5 LPL

2.14e-0513983CID000169871
DrugAC1N8H7N

ABCB1 GUSB UGT2A1 UGT2B15 UGT2B17

2.19e-0578985CID004318740
DrugSotalol hydrochloride [959-24-0]; Up 200; 13uM; MCF7; HT_HG-U133A

DOCK4 TRPC1 APAF1 F5 SLC44A1 SLC16A4 PCNX4

2.25e-051969877338_UP
DrugAsiaticoside [16830-15-2]; Up 200; 4.2uM; HL60; HT_HG-U133A

TRIM58 ADAMTS13 ALDH1L1 SLC6A6 SLC44A1 SLC16A4 LRP5

2.25e-051969872943_UP
DrugNilutamide [63612-50-0]; Up 200; 12.6uM; MCF7; HT_HG-U133A

DPT ALDH1L1 ACVR1B SLC6A6 FRMD4A TENM4 ALK

2.40e-051989876481_UP
Drug2-propylpentanoic acid; Down 200; 500uM; PC3; HT_HG-U133A

DRD2 TRPC1 APAF1 ACVR1B NEB PTPRB MAST4

2.40e-051989874464_DN
Drugtestosterone glucuronide

GUSB UGT2A1 UGT2B15 UGT2B17

2.89e-0541984CID000108192
DrugSCH 23390

DRD2 SWT1 RYR2 CNOT6L TAS1R1 UGT2B15 RASSF9 ALG1

3.25e-05285988ctd:C534628
Drugsilibinin

ABCB1 GUSB UGT2A1 UGT2B15 UGT2B17 PRKCE PRKCH ALK

3.25e-05285988CID000005213
Drugbutylated hydroxytoluene

COQ3 UGT2A1 UGT2B15 UGT2B17 PRKCE PRKCH

3.62e-05143986CID000031404
Drugmenthol

MRGPRD UGT2A1 UGT2B15 UGT2B17 PRKCE

3.73e-0587985CID000001254
Drug4-aminobiphenyl

GUSB UGT2A1 UGT2B15 UGT2B17 GSTO1

4.87e-0592985CID000007102
DrugNSC 36363

DRD2 ABCB1 GUSB

5.03e-0517983CID000005417
Drugsalicylamide

GUSB UGT2A1 UGT2B15 UGT2B17

5.43e-0548984CID000005147
DrugN-n-propylnorapomorphine

DRD2 ABCB1

5.49e-053982ctd:C009074
Drugdihydrozeatin

GUSB UGT2A1 SLC28A1

6.02e-0518983CID000032021
DrugCgp-42700

ABCB1 PRKCE PRKCH

6.02e-0518983CID000188390
DrugC1 11-32

UGT2A1 UGT2B15 UGT2B17

6.02e-0518983CID000443077
DrugC11131

UGT2A1 UGT2B15 UGT2B17

6.02e-0518983CID000443076
Druglidocaine

RET RYR2 ABCB1 SCN7A PRKCE PRKCH

6.77e-05160986CID000003676
DrugAC1NQGK1

GUSB UGT2A1 UGT2B15 UGT2B17

7.46e-0552984CID005195977
Drugoxazepam

GUSB UGT2A1 UGT2B15 UGT2B17

8.04e-0553984CID000004616
DrugAC1L1OBF

GUSB UGT2B15 UGT2B17

8.36e-0520983CID000032736
Drugbeta-alanine

MRGPRD SLC1A5 SLC6A6 SLC28A1 MED12

8.75e-05104985CID000000239
Drugchrysin

ABCB1 GUSB UGT2A1 UGT2B15 UGT2B17

9.58e-05106985CID005281607
Drugestriol-16-glucuronide

UGT2A1 UGT2B15 UGT2B17

9.72e-0521983CID000122281
Drugfluconazole

CPZ ABCB1 UGT2A1 UGT2B15 UGT2B17

1.00e-04107985CID000003365
Drug7-methoxycoumarin

GUSB UGT2A1 UGT2B15 UGT2B17

1.07e-0457984CID000010748
Drugtaxinine K

ABCB1 BTK

1.09e-044982CID005321708
Druglithocholate-3-O-glucuronide

ABCB1 GUSB

1.09e-044982CID000126511
Drug3,4,5,6-tetrahydroxyxanthen-9-one

GUSB LPL

1.09e-044982CID010015450
Drugbis(3-aminopropyl)methylamine

DPT ABCB1

1.09e-044982CID000007777
Drugphenolphthalein

GUSB UGT2A1 UGT2B15 UGT2B17

1.15e-0458984CID000004764
Drugsodium linoleate

DPT ELOVL1 LPL LRP1 LRP6 PRKCE ACMSD SLC27A2

1.16e-04342988CID000003931
Drugvitamin E

COQ3 ABCB1 LPL LRP1 LRP6 LRP5 PRKCE PRKCH GSTO1

1.21e-04441989CID000002116
Drug4-hydroxybiphenyl

GUSB UGT2A1 UGT2B15 UGT2B17

1.22e-0459984CID000007103
Drugacetaminophen glucuronide

GUSB UGT2A1 UGT2B15 UGT2B17

1.22e-0459984CID000083944
Druglithocholic acid

GUSB UGT2A1 UGT2B15 UGT2B17 SLC27A2

1.47e-04116985CID000009903
DrugNimodipine [66085-59-4]; Up 200; 9.6uM; HL60; HT_HG-U133A

DOCK4 DRD2 ACVR1B LRP1 PRKCH ALK

1.50e-041859863103_UP
Druganethole trithione

DPT UGT2B15 UGT2B17 MED12

1.58e-0463984CID000002194
Drug3-OHBaP

GUSB UGT2A1 UGT2B15 UGT2B17

1.58e-0463984CID000025890
DrugHymecromone

UGT2A1 UGT2B15 UGT2B17

1.66e-0425983ctd:D006923
Druguridine 5'-diphosphoglucuronic acid

SLC1A5 NUDT1 GUSB UGT2A1 UGT2B15 UGT2B17

1.69e-04189986CID000000390
DrugNSC-687962

ABCB1 GUSB

1.82e-045982CID000390521
DrugLF 433

GUSB LPL

1.82e-045982CID000068715
DrugETYA

GUSB LPL PRKCE PRKCH SLC27A2

1.86e-04122985CID000001780
DrugXylazine [7361-61-7]; Up 200; 18.2uM; HL60; HT_HG-U133A

NBEA ALDH1L1 NEB F5 RYR2 DNAJC28

2.00e-041959862132_UP
DrugBufexamac [2438-72-4]; Down 200; 18uM; HL60; HT_HG-U133A

DDX60 ALDH1L1 RET NEB LRP5 ALK

2.06e-041969862382_DN
Drug2-propylpentanoic acid; Up 200; 200uM; HL60; HT_HG-U133A

DOCK4 TRIM58 ALDH1L1 F5 SLC44A1 SLC16A4

2.06e-041969861155_UP
DrugCefotiam hydrochloride; Up 200; 7.2uM; HL60; HT_HG-U133A

ALDH1L1 ACVR1B F5 SLC6A6 SLC16A4 PRKCE

2.06e-041969862458_UP
DrugMethimazole [60-56-0]; Up 200; 35uM; MCF7; HT_HG-U133A

DRD2 APAF1 ACVR1B NEB F5 SLC16A4

2.06e-041969864372_UP
Drugbeta-tocopherol

PRKCE PRKCH ALG1

2.10e-0427983CID000008989
Drugilmofosine

ABCB1 PRKCE PRKCH

2.10e-0427983CID000055008
Drugpseudohypericin

ABCB1 PRKCE PRKCH

2.10e-0427983CID005281751
DrugN-Acetyl-L-leucine [1188-21-2]; Up 200; 23uM; HL60; HT_HG-U133A

DRD2 TRPC1 APAF1 ACVR1B PRKCE SCIN

2.11e-041979863085_UP
DrugUrosiol [128-13-2]; Up 200; 10.2uM; HL60; HT_HG-U133A

DRD2 ALDH1L1 F5 FRMD4A LRP5 SCIN

2.11e-041979863105_UP
Druggenistein; Down 200; 10uM; MCF7; HT_HG-U133A

ADAMTS13 ACVR1B MAST4 SLC16A4 NYNRIN ALK

2.11e-041979865595_DN
DrugRapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A

DRD2 APAF1 NBEA ALDH1L1 ACVR1B NEB

2.11e-041979862702_DN
DrugMephenesin [59-47-2]; Down 200; 22uM; MCF7; HT_HG-U133A

TRPC1 NEB RYR2 SLC44A1 LRP6 TTC33

2.11e-041979862304_DN
DrugPirenperone [ 75444-65-4]; Up 200; 10.2uM; MCF7; HT_HG-U133A

DRD2 TRPC1 ADAMTS13 ALDH1L1 F5 PRKCE

2.11e-041979863316_UP
DrugDehydrocholic acid [81-23-2]; Up 200; 9.6uM; MCF7; HT_HG-U133A

TRPC1 APAF1 ALDH1L1 ACVR1B MAST4 NYNRIN

2.11e-041979865681_UP
Drug(+)-Isoproterenol (+)-bitartrate salt [14638-70-1]; Down 200; 11uM; PC3; HT_HG-U133A

NEB RYR2 SLC44A1 MAST4 LRP1 SCIN

2.11e-041979866663_DN
DrugAC1L1H7H

LPL PRKCE PRKCH SCIN

2.13e-0468984CID000004009
DrugIopamidol [60166-93-0]; Up 200; 5.2uM; HL60; HT_HG-U133A

LRRC8E DRD2 TRPC1 F5 PRKCH ALK

2.17e-041989862732_UP
DrugDiperodon hydrochloride [537-12-2]; Down 200; 9.2uM; PC3; HT_HG-U133A

DRD2 ACVR1B SLC44A1 DNAJC28 LRP1 LRP6

2.17e-041989864498_DN
DrugPantothenic acid calcium salt monohydrate [63409-48-3]; Up 200; 8uM; PC3; HT_HG-U133A

F5 RYR2 FRMD4A MAST4 LRP1 RASSF9

2.17e-041989864189_UP
DrugBetulinic acid [472-15-1]; Down 200; 8.8uM; MCF7; HT_HG-U133A

NEB SLC44A1 DNAJC28 LRP6 PRKCE ALK

2.17e-041989863281_DN
DrugBenperidol [2062-84-2]; Up 200; 10.4uM; PC3; HT_HG-U133A

ACVR1B SLC6A6 FRMD4A LRP1 PRKCE RASSF9

2.17e-041989864196_UP
DrugBisoprolol fumarate; Up 200; 9uM; PC3; HT_HG-U133A

ALDH1L1 ACVR1B NEB FRMD4A LPL PRKCE

2.17e-041989866748_UP
DrugNilutamide [63612-50-0]; Down 200; 12.6uM; MCF7; HT_HG-U133A

RYR2 SLC44A1 DNAJC28 LRP6 PRKCH TTC33

2.17e-041989866481_DN
DrugPropranolol hydrochloride [318-98-9]; Up 200; 13.6uM; MCF7; HT_HG-U133A

NEB FRMD4A SLC44A1 MAST4 DNAJC28 PRKCE

2.23e-041999865358_UP
DrugChenodiol [474-25-9]; Down 200; 10.2uM; HL60; HT_HG-U133A

SART3 ALDH1L1 NEB F5 LRP6 ALK

2.23e-041999862402_DN
DrugLobeline alpha (-) hydrochoride [134-63-4]; Up 200; 10.6uM; MCF7; HT_HG-U133A

ADAMTS13 ALDH1L1 ACVR1B RYR2 SLC6A6 SLC16A4

2.23e-041999862763_UP
DrugCephapirin sodium salt [24356-60-3]; Up 200; 9uM; MCF7; HT_HG-U133A

DRD2 ALDH1L1 NEB F5 SLC6A6 PRKCE

2.23e-041999866790_UP
DrugPodophyllotoxin [518-28-5]; Down 200; 9.6uM; PC3; HT_HG-U133A

TRPC1 TMEM187 PTGFR MAST4 DNAJC28 LRP6

2.23e-041999865841_DN
Drugwortmannin from Penicillium funiculosum; Down 200; 0.01uM; MCF7; HT_HG-U133A

TRPC1 ADAMTS13 ALDH1L1 ACVR1B SLC6A6 SLC44A1

2.29e-042009865603_DN
DrugMeglumine [6284-40-8]; Up 200; 20.4uM; HL60; HT_HG-U133A

DRD2 TRPC1 ADAMTS13 ALDH1L1 ACVR1B RYR2

2.29e-042009863068_UP
Druggingerol

APAF1 ABCB1 LRP6 PRKCE

2.38e-0470984ctd:C007845
DrugR59949

CEPT1 LPL PRKCE PRKCH

2.38e-0470984CID000657356
Drugphloretin

TTYH3 PTGFR LPL PRKCE PRKCH

2.58e-04131985CID000004788
Drugvery low density lipoprotein triglyceride

LPL LRP1

2.72e-046982ctd:C030106
Drug7-hydroxyamoxapine

DRD2 GUSB

2.72e-046982CID000162242
DiseaseAbnormality of the sense of smell, COVID-19 symptoms measurement, ageusia

UGT2A2 UGT2A1

1.07e-052972EFO_0600019, EFO_1001758, HP_0004408
Diseaserevision of total joint arthroplasty, aseptic loosening

ELAPOR2 SLC6A6 SLC28A1

1.87e-0516973EFO_0010725, EFO_0020974
DiseaseColorectal Carcinoma

STARD8 CD109 ETFDH ALDH1L1 RET F5 PTPRT ABCB1 LRP1 PRKCE MUTYH

1.99e-057029711C0009402
Diseasecholic acid glucuronide measurement

UGT2B15 UGT2B17

3.20e-053972EFO_0800574
DiseaseX-25937 measurement

UGT2B15 UGT2B17

6.39e-054972EFO_0800937
Diseaseepiandrosterone sulfate measurement

UGT2B15 UGT2B17 ALK

7.52e-0525973EFO_0021120
DiseaseIschemic stroke

ELAPOR2 PRPF8 F5 PTPRT NYNRIN TMEM184C SLC26A11

9.95e-05324977HP_0002140
DiseaseSTROKE, ISCHEMIC

F5 PRKCH

1.06e-045972601367
DiseaseIschemic stroke

F5 PRKCH

1.06e-045972cv:C0948008
DiseaseHIRSCHSPRUNG DISEASE, SUSCEPTIBILITY TO, 1

RET MED12

1.59e-046972C3888239
Diseaseandrosterone sulfate measurement

UGT2B15 UGT2B17 ALK

1.75e-0433973EFO_0021117
Diseaselaurylcarnitine measurement

ETFDH ABCB1

2.22e-047972EFO_0021041
DiseaseX-24574 measurement

UGT2B15 UGT2B17

2.22e-047972EFO_0800897
Diseaseserum metabolite measurement

TRIM58 ETFDH GUSBP1 ALDH1L1 PTPRT FAM151B LPL SLC28A1 UGT2B15 PRKCE ALK

2.77e-049459711EFO_0005653
Diseasefamilial hyperlipidemia (is_implicated_in)

ABCB1 LPL

2.96e-048972DOID:1168 (is_implicated_in)
Diseasedeoxycholic acid glucuronide measurement

UGT2B15 UGT2B17

2.96e-048972EFO_0800575
Diseasebrain ischemia (biomarker_via_orthology)

DRD2 APAF1 RET ABCB1

3.64e-04102974DOID:2316 (biomarker_via_orthology)
Diseasealcohol use disorder (implicated_via_orthology)

DRD2 RYR2 PRKCE PRKCH GSTO1

4.72e-04195975DOID:1574 (implicated_via_orthology)
Disease4-androsten-3alpha,17alpha-diol monosulfate (3) measurement

UGT2B15 UGT2B17

4.73e-0410972EFO_0022090
Diseasemetabolite measurement

ETFDH ALDH1L1 WDFY4 LPL SLC28A1 UGT2B15 UGT2B17 ACMSD

5.27e-04560978EFO_0004725
Diseasecholestasis (biomarker_via_orthology)

ADAMTS13 ALDH1L1 ABCB1

5.69e-0449973DOID:13580 (biomarker_via_orthology)
DiseaseDrug habituation

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C0013170
DiseaseDrug abuse

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C0013146
DiseasePrescription Drug Abuse

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C4316881
DiseaseSubstance-Related Disorders

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C0236969
DiseaseDrug Use Disorders

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C0013222
DiseaseDrug Dependence

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C1510472
DiseaseSubstance Dependence

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C0038580
DiseaseSubstance Use Disorders

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C0038586
DiseaseOrganic Mental Disorders, Substance-Induced

DRD2 FRMD4A PRKCE PRKCH

5.74e-04115974C0029231
DiseasePosterior Choroidal Artery Infarction

F5 PRKCH

5.77e-0411972C0887799
DiseaseCerebral Infarction, Left Hemisphere

F5 PRKCH

5.77e-0411972C0751010
DiseaseAnterior Choroidal Artery Infarction

F5 PRKCH

5.77e-0411972C0751012
DiseaseCerebral Infarction, Right Hemisphere

F5 PRKCH

5.77e-0411972C0751011
DiseaseSubcortical Infarction

F5 PRKCH

5.77e-0411972C0751014
DiseaseCerebral Infarction

F5 PRKCH

5.77e-0411972C0007785
DiseaseDNA repair protein RAD51 homolog 4 measurement

UGT2B15 UGT2B17

5.77e-0411972EFO_0801531
DiseaseCognitive impairment

PTPRT RYR2

5.77e-0411972HP_0100543
DiseaseSubstance abuse problem

DRD2 FRMD4A PRKCE PRKCH

5.93e-04116974C0740858
Diseaseomega-3 polyunsaturated fatty acid measurement

MRGPRD LPL UGT2B15 UGT2B17

6.32e-04118974EFO_0010119
Diseasenicotine dependence (implicated_via_orthology)

DRD2 TRPC1

6.91e-0412972DOID:0050742 (implicated_via_orthology)
Disease5alpha-androstan-3beta,17beta-diol monosulfate (2) measurement

UGT2B15 UGT2B17

6.91e-0412972EFO_0800291
Diseaseandrostenediol (3alpha, 17alpha) monosulfate (3) measurement

UGT2B15 UGT2B17

8.15e-0413972EFO_0800293
DiseaseX-19141 measurement

UGT2B15 UGT2B17

8.15e-0413972EFO_0800799
Diseasevenous thromboembolism

DPT ADAMTS13 F5 PTPRT PRKCE PRKCH DLEC1

8.22e-04460977EFO_0004286
Diseaseplatelet component distribution width

STARD8 TRIM58 RTTN TTYH3 FAM187B NYNRIN LPL DLEC1 EIF2AK4

8.63e-04755979EFO_0007984
Diseasediffuse plaque measurement

DRD2 CD109 ALDH1L1 FRMD4A SLC44A1 TENM4 MAST4 DLEC1 RASSF9

8.87e-04758979EFO_0010699
Disease5alpha-androstan-3alpha,17alpha-diol monosulfate measurement

UGT2B15 UGT2B17

9.49e-0414972EFO_0800283
DiseasePolyposis, Adenomatous Intestinal

F5 MUTYH

1.25e-0316972C2713442
DiseaseFamilial Intestinal Polyposis

F5 MUTYH

1.25e-0316972C2713443
DiseaseMajor Depressive Disorder

DRD2 APAF1 ABCB1 LRP1 MED12

1.27e-03243975C1269683
Diseasemean reticulocyte volume

TMEM50A TRIM58 RTTN TMEM187 NEB SLC16A4 NYNRIN LPL MAST1

1.28e-03799979EFO_0010701
Diseasenon-alcoholic fatty liver disease (biomarker_via_orthology)

ADAMTS13 ABCB1 LPL

1.30e-0365973DOID:0080208 (biomarker_via_orthology)
DiseaseCannabis Dependence

DRD2 ABCB1

1.41e-0317972C0006870
DiseaseAdenomatous Polyposis Coli

F5 MUTYH

1.41e-0317972C0032580
Diseaseradiation-induced disorder

TRPC1 PRKCH DLEC1

1.42e-0367973EFO_0009565
DiseaseTachycardia

DRD2 RYR2

1.58e-0318972C0039231
DiseaseAdrenocortical carcinoma

ABCB1 MED12

1.58e-0318972C0206686
DiseaseTachyarrhythmia

DRD2 RYR2

1.58e-0318972C0080203
Disease5alpha-androstan-3alpha,17beta-diol monosulfate (1) measurement

UGT2B15 UGT2B17

1.58e-0318972EFO_0800288
DiseaseUnipolar Depression

DRD2 APAF1 ABCB1 LRP1 MED12

1.68e-03259975C0041696
Diseaseasthma, response to diisocyanate

DPT GUSBP1 PTPRT PRKCE ACMSD

1.73e-03261975EFO_0006995, MONDO_0004979
Diseaseetiocholanolone glucuronide measurement

UGT2B15 UGT2B17

1.76e-0319972EFO_0800362
Diseaseamino acid measurement

DCDC1 PTGFR RYR2 PTPRB TENM4 PRKCE ALK ALG1

1.79e-03678978EFO_0005134
Diseasenucleotide measurement

PTPRB PRKCE ALK

1.81e-0373973EFO_0010513
Diseasecoagulation factor V measurement

F5 MAST4

1.96e-0320972EFO_0008087
Diseaseseborrheic dermatitis

ELAPOR2 MAST4

1.96e-0320972EFO_1000764
Diseaseandrosterone glucuronide measurement

UGT2B15 UGT2B17

1.96e-0320972EFO_0800317
DiseaseBreast Carcinoma

STARD8 CD109 ABCB1 BTK SLC28A1 ALK MED12

2.02e-03538977C0678222
Diseaseepilepsy (implicated_via_orthology)

SLC1A5 ABCB1 SCN7A LRP1

2.09e-03163974DOID:1826 (implicated_via_orthology)
DiseaseColorectal Neoplasms

STARD8 CD109 RET ABCB1 PRKCE

2.24e-03277975C0009404
Diseasereticulocyte count

TMEM50A TRIM58 PRPF8 FAM187B LPL MAST1 LRP5 PRKCE EIF2AK4 MED12

2.31e-0310459710EFO_0007986
DiseaseX-24947 measurement

UGT2B15 UGT2B17

2.37e-0322972EFO_0800910
Diseasehigh density lipoprotein particle size measurement

ETFDH LPL UGT2B15 UGT2B17

2.43e-03170974EFO_0008592
DiseaseOvarian Serous Adenocarcinoma

MAST1 ALK

2.59e-0323972C1335177
Diseasesensory peripheral neuropathy, remission

PTPRT DLEC1

2.59e-0323972EFO_0009785, MONDO_0002321
Diseasebeverage consumption measurement

DOCK4 RYR2 ACMSD

2.62e-0383973EFO_0010088
Diseaselung adenocarcinoma (is_marker_for)

SLC1A5 PTPRB BTK

2.80e-0385973DOID:3910 (is_marker_for)
Diseasetestosterone measurement

DOCK4 STARD8 DCDC1 UGT2A2 NYNRIN UGT2A1 SLC28A1 UGT2B15 UGT2B17 LRP5 MED12

3.12e-0312759711EFO_0004908
Diseasecigarettes per day measurement

DRD2 DCDC1 SWT1 RET PTGFR LPL

3.28e-03438976EFO_0006525

Protein segments in the cluster

PeptideGeneStartEntry
ILWMVPIYSLDSWIA

TMEM184C

86

Q9NVA4
WKMLYQDELFQWLGK

TRHDE

1006

Q9UKU6
MLISAGGYIKWWNVV

APAF1

1191

O14727
TMVLVSWIMWYAPVG

SLC1A5

266

Q15758
SWIMWYAPVGIMFLV

SLC1A5

271

Q15758
MWPDDSYWFPLLLQK

NUDT1

116

P36639
WKLMWREPGAYIFLQ

ALG1

116

Q9BT22
YEWVLQWQKKMGPFL

EIF2AK4

311

Q9P2K8
AILWLLGSGYSIWMP

ACER1

91

Q8TDN7
WAFGVLMWEIYSLGK

BTK

581

Q06187
IPNWWQSYEALRVMG

ACVR1B

456

P36896
KWWDEQGVYAPLHSM

COQ3

106

Q9NZJ6
KYWLPWLVGMPAETT

ACMSD

186

Q8TDX5
LWVLLPLVTMAWGQY

DPT

6

Q07507
LRGQYWTLQSWVPEM

ADAMTS13

1401

Q76LX8
ILKLWKAWGDEQPNM

RASSF9

96

O75901
LSWKRYQPCWVLMVS

ARHGAP11B

226

Q3KRB8
SFWRIMKLNLTEWPY

ABCB1

696

P08183
LKEKAIQVWDMPSYW

OTOA

881

Q7RTW8
SRVENPLWNKLTYMW

DCDC1

881

M0R2J8
MWQTPVAEWEKYIIS

PTPRB

486

P23467
YWISWVRQMPGKGLE

IGHV5-10-1

51

A0A0J9YXX1
GGNSISMIDYLIWPW

GSTO1

166

P78417
YAVLTWLSQTLWMPI

HACD4

141

Q5VWC8
WLSQTLWMPIYPLCV

HACD4

146

Q5VWC8
YWMSWVRQAPGKGLE

IGHV3-7

51

P01780
PSVDWWALGVLMYEM

PRKCE

586

Q02156
RAIVVDPLNGWMYWT

LRP1

651

Q07954
GLMYWTDWGENPKIE

LRP5

471

O75197
IQLYDAMFQIWKSWP

DDX60

1031

Q8IY21
RMATWNQILDPWVYI

PTGFR

291

P43088
YVNQIILFLMPWVWG

PCNX4

41

Q63HM2
GWTVTGMYESWVPKL

LPL

81

P06858
WKLLFLMKSQGWLPQ

FAM205C

76

A6NFA0
WHPEKVNEGYSWTMV

FAM151B

171

Q6UXP7
TPEIKKGFLNWMNLW

DNAJC28

366

Q9NX36
WFVLYWLSLPPEMQV

MRGPRD

241

Q8TDS7
FMYWTDWGEVPKIER

LRP6

151

O75581
DPFMEWTQIITKYLW

MED12

181

Q93074
KPWWDVLAEYLTVAM

LRRC8E

21

Q6NSJ5
YWMHWVRQAPGKGLV

IGHV3-74

51

A0A0B4J1X5
LGFEYKWWNVLPGNM

ELAPOR2

436

A8MWY0
KPVDWWAMGIILYEF

MAST1

566

Q9Y2H9
IPLMKISPWWYFAVI

MFSD14A

116

Q96MC6
YWIGWVRQMPGKGLE

IGHV5-51

51

A0A0C4DH38
GFTWEQINTWEKPML

PTPRT

51

O14522
TWYACPALIKSIWAM

FRMD4A

296

Q9P2Q2
TGIFYWILRGMEPWT

ETFDH

471

Q16134
PETWIWLDTNMGYRI

CD109

691

Q6YHK3
RSLLEPLMQGYWEWL

CEPT1

61

Q9Y6K0
TDEWKGWMQLVILIY

CASD1

431

Q96PB1
HYWWGKVAPETKAIM

CPZ

351

Q66K79
STLRDWGTMWKQLYV

DOCK4

91

Q8N1I0
WMAAIGPKRYQDSLW

B3GALNT2

446

Q8NCR0
KVPGVSLWWPYLMHE

GUSB

281

P08236
AQPYLWWKKHMTAIQ

ELOVL1

191

Q9BW60
GKPVDWWAMGIILYE

MAST4

761

O15021
KISGPLQYMWWYHVV

SLC44A1

376

Q8WWI5
MPCWLYLGEVLVWSS

FAM187B

176

Q17R55
LVMPWVVYLEVVGEW

DRD2

86

P14416
KVLGANLWWPYLMHE

GUSBP1

56

Q15486
MWNNSKSPIRYLWGK

DLEC1

781

Q9Y238
PWTVALWSRYLLAME

SART3

376

Q15020
ELWVMNKIELGWQYG

RYR2

891

Q92736
ETYKKLRLLGWWPGM

NYNRIN

1561

Q9P2P1
PVSDMLRIAWNLSWY

RTTN

1016

Q86VV8
GPWMKYSWAVITPVL

SLC6A6

501

P31641
WWIIIDAAVIYPTMK

TMEM50A

36

O95807
MWGYLSLMPVFLAVW

TMEM150B

1

A6NC51
TLEMKASKPGWWLLN

F5

1871

P12259
MLLDAWEQIFIWIGK

SCIN

646

Q9Y6U3
MGNEPAYVWLWLGLV

SLC27A2

111

O14975
VWQDWMFSLGYINPK

NBEA

891

Q8NFP9
YTGWMQKWPTLQDLA

MUTYH

146

Q9UIF7
MWNTEIPYLLISGSW

WDR17

616

Q8IZU2
GNLWMEILYLKPPWT

SWT1

606

Q5T5J6
FMEKYTVPHKQGWVW

STARD8

536

Q92502
YAIMISRPAWLWGAE

SCRN1

66

Q12765
AYEGLSLWQWMVLPL

ALK

586

Q9UM73
IPWNYPLMMLSWKTA

ALDH1L1

571

O75891
PSWALNWEYRKKGIM

CNOT6L

211

Q96LI5
IEPVYISQWGSMWIM

PRPF8

136

Q6P2Q9
IIGMIWSDIKRLWYE

TRPC1

431

P48995
WVPVRDIIMHPKYWG

PRSS45P

61

Q7RTY3
VETMVLLLQKFGWTW

TAS1R1

196

Q7RTX1
YTKTLDGGWGWMIVI

SLC16A4

11

O15374
SKPEWYLAQVLMWIG

RINT1

331

Q6NUQ1
ILAWLPSYSLQWLKM

SLC26A11

36

Q86WA9
PLWEETMLKAWQHYL

WDFY4

2161

Q6ZS81
TGWWIMIDAAVVYPK

TMEM50B

36

P56557
WLVVPDGQVYWVTMG

TENM4

1641

Q6N022
YHVGLMQWVILKIAW

SLC28A1

281

O00337
WIENKLYGMSDPNWP

RET

1056

P07949
AMALLYGPVQWLRLW

TMEM187

91

Q14656
LGKYWPTFQILMWSL

SCN7A

606

Q01118
VLVWPTEYSHWINMK

UGT2B15

26

P54855
ENGLIIVWMLYKGSW

WDR35

91

Q9P2L0
MAGVSYAAPWWVSLL

TTYH3

1

Q9C0H2
TMGKAEIWLIRTYWD

UGT2A1

291

P0DTE4
VWALWLLKGNEYMVL

TRIM58

381

Q8NG06
VLVWPTEYSHWINMK

UGT2B17

26

O75795
TMGKAEIWLIRTYWD

UGT2A2

256

P0DTE5
IYPMNPEIWKEDLSW

TTC33

156

Q6PID6
LQEMLYGPAVDWWAM

PRKCH

526

P24723
VYKADLEWLRGIGWM

NEB

4111

P20929